CD19 and leukemia: In addition, we evaluated 2nd-gen anti-CD19 4-1BBζ-CAR T cell products generated from four patients either with B-ALL leukaemia (PD323, PD356 and PD674) or non-B-ALL lung cancer (PD145) (Fig. 5f and Extended Data Fig. 6a,b).